Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared With Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age.

The purpose of this study was to demonstrate the non-inferior HAI immune response of quadrivalent recombinant influenza vaccine (RIV4) vs licensed Egg-Based Quadrivalent Influenza Vaccine (IIV4) for the 4 strains based on the egg-derived antigen in all participants aged 3 to 8 years and to describe the immunogenicity and safety profile of RIV4 compared to IIV4 in participants aged 3 to 8 years.

Start Date10 Nov 2022

Sponsor / Collaborator

Sanofi Pasteur SA

NCT05409612

/ CompletedPhase 3IIT

Multicenter, Randomized, Open, Phase III, Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients

Obesity has been considered as a risk factor for mortality and development of complications during infection with the influenza virus. Several case studies of severe and fatal infections have identified possible effects of obesity on disease progression; these effects include extensive viral replication in the deep lung, progression to viral pneumonia, and prolonged and increased viral shedding. These points may be linked to obesity which causes a chronic state of meta-inflammation with systemic implications for immunity: obese patients exhibit delayed and blunted innate and adaptive immune responses to influenza virus infection, and they experience poor recovery from the disease leading to an increased susceptibility to secondary bacterial infections and poor healing of the lung epithelium. Furthermore, in obese people, influenza virus may exploit the lack of antiviral pressure, generate a more virulent population and increase disease severity Due to the growing prevalence of obesity worldwide (500 million subjects in 2017), it is important to be able to offer vaccines that provide the highest protection for this at-risk population. The quadrivalent recombinant high-dose influenza vaccine has been shown to have greater immunogenicity and efficacy than standard influenza vaccine in non-obese adults older than 50 years. However, this vaccine has never been evaluated in obese subjects.
Investigators thus planned this trial to assess whether the use of the new quadrivalent recombinant high-dose influenza vaccine (RIV4) will induce a better immunological answer than current quadrivalent standard vaccine (SD) in patients with severe obesity, with an acceptable safety profile, thus leading to a better protection against influenza in this population at high risk of influenza complications.

Start Date07 Nov 2022

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

[+2]

NCT05513053

/ CompletedPhase 3

Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years.

The purpose of this study was to demonstrate the non-inferiority (NI) of the HAI immune response of RIV4 in participants aged 9 to 17 years vs participants aged 18 to 49 years and to describe the immunogenicity and safety profile of RIV4 in all participants.

Start Date27 Oct 2022

Sponsor / Collaborator

Sanofi Pasteur SA

100 Clinical Results associated with Recombinant Influenza vaccine quadrivalent(Protein Sciences Corp.)

100 Translational Medicine associated with Recombinant Influenza vaccine quadrivalent(Protein Sciences Corp.)

100 Patents (Medical) associated with Recombinant Influenza vaccine quadrivalent(Protein Sciences Corp.)

Literatures (Medical) associated with Recombinant Influenza vaccine quadrivalent(Protein Sciences Corp.)

01 May 2025·LANCET INFECTIOUS DISEASES

Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study

Article

Author: See, Stephanie ; De Bruijn, Iris ; Kaas-Leach, Kathleen ; Tabar, Cynthia ; Pepin, Stephanie ; Konieczny, Marek ; Folegatti, Pedro M ; Drazan, Daniel ; Essink, Brandon ; Natalini Martínez, Silvina ; Bertoch, Todd ; Talanova, Oxana ; Fries, Katherine

BACKGROUND:

The recombinant influenza vaccine (RIV) is licensed for adults older than 18 years but is not approved for paediatric groups. This study aimed to demonstrate the non-inferior immune responses and safety of RIV in participants aged 9-17 years compared with adults aged 18-49 years.

METHODS:

This was a phase 3, non-randomised, immunobridging, open-label, uncontrolled study conducted at 36 centres in Europe and the USA during the 2022-23 northern hemisphere influenza season. The main exclusion criteria were receipt of an influenza vaccine up to 6 months before enrolment and receipt of any other vaccines within 4 weeks before or after study intervention (except for COVID-19 vaccination, which was allowed at least 2 weeks before or after enrolment). Healthy participants aged 9-49 years received a single dose of quadrivalent RIV and were followed up for 6 months on days 9, 29, and 181. Haemagglutination inhibition (HAI) assays to assess immunogenicity were used to test blood samples obtained at baseline and day 29. The primary outcome was the non-inferiority of immune response at day 29 as assessed by HAI titre ratios and differences in seroconversion rates between the two age groups. The non-inferiority of a geometric mean titre was demonstrated if the lower limit of the two-sided 95% CI of the geometric mean titre (GMT) ratio was above 0·667 for each of the four strains of virus. Similarly, the non-inferiority of seroconversion was demonstrated if the lower limit of the two-sided 95% CI was -10% or above for each of four strains. Safety was monitored throughout the study. This study was registered at ClinicalTrials.gov (NCT05513053) and is complete.

FINDINGS:

Between Oct 27, 2022, and May 1, 2023, a total of 1308 participants were enrolled, all of whom attended the first study visit. 1299 participants (99%) received the study vaccine (641 participants [49%] in the age 9-17 years group and 658 participants [51%] in the age 18-49 years group). The mean age of participants in the age 9-17 years group was 13·0 years (SD 2·5) and was 34·3 years (9·2) in the age 18-49 years group. Overall, 707 participants (54%) were female and 601 participants (46%) were male. Most of the participants were White (1003 [77%] of 1308); the next largest category was Black or African American (255 [19%]); 149 (11%) participants identified as Hispanic or Latino. The HAI GMT ratio between the paediatric and adult groups at day 29 in the per-protocol analysis set was 2·0 (95% CI 1·7 to 2·3), 3·3 (2·8 to 3·9), 1·6 (1·4 to 1·8), and 1·2 (1·1 to 1·4) for A/H1N1, H3N2, B/Victoria, and B/Yamagata, respectively. Differences in seroconversion between the groups were 1·9 (-2·8 to 6·6), -0·6 (-4·4 to 3·2), 3·3 (-1·6 to 8·1), and 14·3 (9·2 to 19·3) for each of the four strains, respectively. The safety profile was comparable in both age groups, except for solicited reactions within 7 days post-vaccination that were fewer in children and adolescents (274 [44%] of 618; 95% CI 40 to 48) than in adults (336 [53%] of 635; 49 to 57). No related serious adverse events, deaths, or adverse events of special interest were reported.

INTERPRETATION:

RIV4 induced non-inferior immune responses in the participants aged 9-17 years compared with those aged 18-49 years. No safety concerns were reported.

FUNDING:

Sanofi.

01 Apr 2025·VACCINE

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18–45 years of age

Article

Author: Frey, Sharon E ; Bryant, Christopher ; Creech, C Buddy ; Alefantis, Timothy ; Abate, Getahun ; Anderson, Evan J ; Tuyishimire, Bonifride ; Rouphael, Nadine ; Makhene, Mamodikoe ; Campbell, James ; Pandey, Aseem ; Sridhar, Saranya ; Rostad, Christina A ; Walter, Emmanuel B ; Petrovsky, Nikolai ; Honda-Okubo, Yoshikazu ; Smith, Michael J ; Winokur, Patricia ; Hegmann, Theresa E ; Goncalvez, Ana P ; El Sahly, Hana M ; Whitaker, Jennifer A ; Paulsen, Grant ; Roberts, Paul C ; Ustyugova, Irina V

Seasonal influenza continues to cause significant morbidity and mortality, particularly for the elderly and immunocompromised. Current licensed influenza vaccines provide only partial protection even for immunocompetent hosts. Vaccine adjuvants can improve the magnitude and breadth of immune responses and there is considerable interest in identifying new adjuvants that can improve immune responses to seasonal influenza vaccines. This phase I, randomized, double-blind trial evaluated the safety and immunogenicity of one dose of 2018/2019 quadrivalent influenza vaccine (either Fluzone® or Flublok®) administered intramuscularly with or without one of two adjuvants (AF03 or Advax-CpG55.2). A total of 241 healthy adults aged 18-45 years were enrolled and randomized to 1 of 6 groups. Groups 1-3 received one dose of Fluzone® QIV 2018/2019 administered alone or with AF03 or Advax-CpG55.2 and Groups 4-6 received one dose of Flublok® QIV 2018/2019 alone or with one of these two adjuvants. All participants received Fluzone® or Flublok® QIV 2019/2020 ninety days later. Primary objectives were to evaluate safety and reactogenicity along with changes in hemagglutinin inhibition (HAI), neuraminidase inhibition (NAI) and neutralizing antibodies to 2018/2019 seasonal influenza antigens, comparing Day 1 and Day 29 titers. Secondary objectives evaluated the impact of adjuvants on immune responses after subsequent doses of unadjuvanted seasonal influenza vaccine and immunologic responses to heterologous influenza H1 and H3 antigens. Overall, the adjuvanted vaccines were safe and generated robust immune responses against both homologous and heterologous strains. Similar responses were seen across all six study arms. Both adjuvants were associated with qualitatively improved immune responses against some strains at varying timepoints, but results were inconsistent. There were no substantial differences in safety or reactogenicity identified between the study groups and all vaccine formulations were well tolerated. In this highly immunologically-experienced cohort, neither AF03 nor Advax-CpG55.2 demonstrated notable benefit when added to the seasonal influenza vaccine. (ClinicalTrials.gov ID# NCT03945825).

01 Feb 2025·Lancet Microbe

Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study

Article

Author: Bartzoka, Foteini ; Sambhara, Suryaprakash ; Kain, Jessica ; Thompson, Mark G ; Gangappa, Shivaprakash ; Liu, Feng ; Kennedy, Richard B ; Cao, Weiping ; Jacob, Joshy ; Schwartz, Evan A ; von Beck, Troy ; McKnight, Eric ; Satterwhite, Ed ; Kim, Jin Eyun ; Towers, Dalton M ; Sharma, Suresh ; Park, Juyeon ; Stevens, James ; Lee, Justin S ; Brilot, Axel F ; Kumar, Amrita ; Gaglani, Manjusha ; Levine, Min Z ; Hebert, Luke S ; Naleway, Allison L ; Ippolito, Gregory C ; Wang, Yuanyuan ; Eddins, Devon J ; Lavinder, Jason J ; Dawood, Fatimah S ; Georgiou, George ; Pohl, Jan ; Mishina, Margarita ; Li, Zhu-Nan

BACKGROUND:

Egg-based inactivated quadrivalent seasonal influenza vaccine (eIIV4), cell culture-based inactivated quadrivalent seasonal influenza vaccine (ccIIV4), and recombinant haemagglutinin (HA)-based quadrivalent seasonal influenza vaccine (RIV4) have been licensed for use in the USA. In this study, we used antigen-specific serum proteomics analysis to assess how the molecular composition and qualities of the serological antibody repertoires differ after seasonal influenza immunisation by each of the three vaccines and how different vaccination platforms affect the HA binding affinity and breadth of the serum antibodies that comprise the polyclonal response.

METHODS:

In this comparative, prospective, observational cohort study, we included female US health-care personnel (mean age 47·6 years [SD 8]) who received a single dose of RIV4, eIIV4, or ccIIV4 during the 2018-19 influenza season at Baylor Scott & White Health (Temple, TX, USA). Eligible individuals were selected based on comparable day 28 serum microneutralisation titres and similar vaccination history. Laboratory investigators were blinded to assignment until testing was completed. The preplanned exploratory endpoints were assessed by deconvoluting the serological repertoire specific to A/Singapore/INFIMH-16-0019/2016 (H3N2) HA before (day 0) and after (day 28) immunisation using bottom-up liquid chromatography-mass spectrometry proteomics (referred to as Ig-Seq) and natively paired variable heavy chain-variable light chain high-throughput B-cell receptor sequencing (referred to as BCR-Seq). Features of the antigen-specific serological repertoire at day 0 and day 28 for the three vaccine groups were compared. Antibodies identified with high confidence in sera were recombinantly expressed and characterised in depth to determine the binding affinity and breadth to time-ordered H3 HA proteins.

FINDINGS:

During September and October of the 2018-19 influenza season, 15 individuals were recruited and assigned to receive RIV4 (n=5), eIIV4 (n=5), or ccIIV4 (n=5). For all three cohorts, the serum antibody repertoire was dominated by back-boosted antibody lineages (median 98% [95% CI 88-99]) that were present in the serum before vaccination. Although vaccine platform-dependent differences were not evident in the repertoire diversity, somatic hypermutation, or heavy chain complementarity determining region 3 biochemical features, antibodies boosted by RIV4 showed substantially higher binding affinity to the vaccine H3/HA (median half-maximal effective concentration [EC50] to A/Singapore/INFIMH-16-0019/2016 HA: 0·037 μg/mL [95% CI 0·012-0·12] for RIV4; 4·43 μg/mL [0·030-100·0] for eIIV4; and 18·50 μg/mL [0·99-100·0] μg/mL for ccIIV4) and also the HAs from contemporary H3N2 strains than did those elicited by eIIV4 or ccIIV4 (median EC50 to A/Texas/50/2012 HA: 0·037 μg/mL [0·017-0·32] for RIV4; 1·10 μg/mL [0·045-100] for eIIV4; and 12·6 μg/mL [1·8-100] for ccIIV4). Comparison of B-cell receptor sequencing repertoires on day 7 showed that eIIV4 increased the median frequency of canonical egg glycan-targeting B cells (0·20% [95% CI 0·067-0·37] for eIIV4; 0·058% [0·050-0·11] for RIV4; and 0·035% [0-0·062] for ccIIV4), whereas RIV4 vaccination decreased the median frequency of B-cell receptors displaying stereotypical features associated with membrane proximal anchor-targeting antibodies (0·062% [95% CI 0-0·084] for RIV4; 0·12% [0·066-0·16] for eIIV4; and 0·18% [0·016-0·20] for ccIIV4). In exploratory analysis, we characterised the structure of a highly abundant monoclonal antibody that binds to both group 1 and 2 HAs and recognises the HA trimer interface, despite its sequence resembling the stereotypical sequence motif found in membrane-proximal anchor binding antibodies.

INTERPRETATION:

Although all three licensed seasonal influenza vaccines elicit serological antibody repertoires with indistinguishable features shaped by heavy imprinting, the RIV4 vaccine selectively boosts higher affinity monoclonal antibodies to contemporary strains and elicits greater serum binding potency and breadth, possibly as a consequence of the multivalent structural features of the HA immunogen in this vaccine formulation. Collectively, our findings show advantages of RIV4 vaccines and more generally highlight the benefits of multivalent HA immunogens in promoting higher affinity serum antibody responses.

FUNDING:

Centers for Disease Control and Prevention, National Institutes of Health, and Bill & Melinda Gates Foundation.

News (Medical) associated with Recombinant Influenza vaccine quadrivalent(Protein Sciences Corp.)

10 Jul 2024

·www.pharmaindustrial-india.com

Sanofi Starts Shipping US Influenza Vaccines for 2024-25

Sanofi has begun shipped its first influenza (flu) vaccines across the U.S. in preparation for the 2024–25 flu season. Following this first shipment, additional shipments of the full Sanofi flu vaccine portfolio will continue through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. With over 125 years of heritage in helping protect global public health, Sanofi is a world leader in vaccines, helping to vaccinate more than 500 million people annually. Thomas Grenier, Head of Vaccines, North America, Sanofi said, "Today, we began shipping flu vaccines for the upcoming season, a moment that underscores our long-standing commitment to providing global protection against disease. Getting a flu shot is imperative to not only help protect against flu infection, but also to help reduce the risks of its potentially severe complications, which can lead to hospitalizations, especially in those most vulnerable. Sanofi understands what these populations need out of their flu shots and works tirelessly from start to finish to provide proven and specific solutions." All flu vaccines provided by Sanofi to the US market are trivalent, meaning they offer protection against the current three strains of influenza (two influenza A strains and one influenza B strain). These strains were selected based on a collaborative review of influenza surveillance by the US Food and Drug Administration (FDA), World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), among other public health experts, as the strains most likely to cause illness in the upcoming flu season. Annual flu vaccination is one of the best ways to help protect against flu and its complications. Public health authorities worldwide reiterate their recommendations for eligible people to be vaccinated every year. As one of the largest providers of influenza vaccines to the United States with a range of options, Sanofi meets immunization needs across the lifespan, from children as young as six months of age through adults 65 years of age and older. This year's 2024/25 US influenza season portfolio includes Fluzone High-Dose (Influenza Vaccine), Flublok (Influenza Vaccine) and Fluzone (Influenza Vaccine). Fluzone, Flublok, and Fluzone High-Dose are vaccines indicated for the prevention of disease caused by influenza A and B strains contained in the vaccine. Fluzone is given to people 6 months of age and older. Flublok is given to people 18 years of age and older. Fluzone High-Dose is given to people 65 years of age and older. Fluzone, Flublok, or Fluzone High-Dose should not be given to anyone who has had a severe allergic reaction to any component of the vaccine (including eggs or egg products for Fluzone and Fluzone High-Dose). In addition, Fluzone and Fluzone High-Dose should not be given to anyone who has had a severe allergic reaction after a previous dose of any influenza vaccine.

Vaccine

10 Jul 2024

·www.pharmaindustrial-india.com

Sanofi Starts Shipping US Influenza Vaccines for 2024-25

Vaccine

02 Feb 2024

·www.pharmaceutical-technology.com

As England’s virus hospitalisations surge flu vaccines evolve

Moderna is leading the mRNA influenza vaccine race with its mRNA-1010 candidate. Image credit: Shutterstock/Cryptographer. England’s National Health Service (NHS) has revealed that flu cases last week were up 75% from the same period last year. Currently at the highest levels this winter, data shows an average of 2,226 patients were in hospital each day with flu. This is up 70% from the end of December, and three-quarters up from the same week in January 2023. Along with flu rates, the NHS said Covid-19 figures remain a concern. Nearly 4,000 patients were in hospital with Covid each day last week, according to a 1 February press release. Vaccines can help protect against the flu and are offered to people every year at higher risk of becoming seriously ill from the virus. Caused by the influenza virus, flu is significantly more serious than the common cold, which is caused by a wide range of viruses. NHS England’s National Clinical Director for Urgent and Emergency Care Julian Redhead said: “As always, I would urge the public to get their flu and Covid vaccines if they are eligible, and continue to come forward for NHS services when you need them.” See Also: LimmaTech secures funding for vaccine technology development GSK seeks to extend RSV vaccine use in adults aged 50-59 There are currently six vaccines in use for the 2023 to 2024 flu season in England, according to the UK Health Security Agency. All the vaccines protect against four subtypes of influenza. The vaccines contain two influenza A and B virus strains. Though these flu vaccines work with high efficacy, that has not stopped companies from exploring the next generation of jabs. Moderna is leading the race with a recent trial win for its mRNA-1010 seasonal influenza vaccine. The investigational mRNA vaccine demonstrated strong results in a Phase III trial showing protection against all four flu strains, as per data released by the company in September 2023. Additionally, Sanofi , Curevac , and Pfizer are all developing mRNA/flu combination vaccines, but some clinical trials have produced mixed results so far. GlobalData states that Moderna is currently the leading the mRNA vaccine charge in infectious diseases. GlobalData is the parent company of Pharmaceutical Technology. Among the six approved flu vaccines in the UK, both Sanofi’s quadrivalent influenza vaccine, and Viatris ’ quadrivalent Influvac subunit Tetra, vaccine are licensed for infants from six months of age. CSL Seqirus’ cell-based quadrivalent influenza vaccine is given to those aged two years and above. AstraZeneca ’s Fluenz Tetra, a live attenuated influenza vaccine (LAIV) is for those between two and 18 years of age. For adults over 18 years of age, Sanofi’s Supemtek, a recombinant quadrivalent influenza vaccine is used. CSL Seqirus’ other adjuvanted quadrivalent influenza vaccine (aQIV) is licensed for use for adults above 65 years of age. In a recent deal with the UKHSA , CSL Seqirus agreed to be on standby in case of a future influenza pandemic. The advance purchase agreement, signed in September 2023, meant that the Australia-headquartered drugmaker is ready to produce more than 100 million influenza pandemic vaccines if called upon. The drugs would be manufactured at the company’s plant in Liverpool. The government is already looking at ways of centralising the procurement of adult flu vaccines, as per a vaccination strategy published in December 2023. Currently, vaccines are obtained by individual NHS GP practices. Moving procurement to a national level could facilitate the co-administration of flu and Covid-19 vaccines, the report said.

VaccineClinical ResultPhase 3Drug ApprovalmRNA

100 Deals associated with Recombinant Influenza vaccine quadrivalent(Protein Sciences Corp.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Influenza, Human	European Union	Sanofi Winthrop Industrie SA	16 Nov 2020
Influenza, Human	Iceland	Sanofi Winthrop Industrie SA	16 Nov 2020
Influenza, Human	Liechtenstein	Sanofi Winthrop Industrie SA	16 Nov 2020
Influenza, Human	Norway	Sanofi Winthrop Industrie SA	16 Nov 2020
Influenza A virus infection	United States	Protein Sciences Corp.	16 Jan 2013
Influenza B virus infection	United States	Protein Sciences Corp.	16 Jan 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Vaccination	Phase 3	United States	Sanofi Pasteur SA	27 Oct 2022
Vaccination	Phase 3	Czechia	Sanofi Pasteur SA	27 Oct 2022
Vaccination	Phase 3	Poland	Sanofi Pasteur SA	27 Oct 2022
Vaccination	Phase 3	Spain	Sanofi Pasteur SA	27 Oct 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05514002 (Pubmed \| Open Forum Infect Dis)	Phase 4	Influenza, Human	3,988	Recombinant Influenza Vaccine (RIV)	gcohilerfr(sdortiqmay) = bvyogtgknv pfdpaygwbk (hagbywgedv )	Positive	27 Sep 2024
				Standard-Dose Inactivated Influenza Vaccine (SD IIV)	gcohilerfr(sdortiqmay) = gfbsnjpkyl pfdpaygwbk (hagbywgedv )
NCT05513391 (CTgov)	Phase 3	Vaccination \| Influenza, Human	366	RIV4 (RIV4)	whwzlxbsct(asujuueqpj) = qqybnfaszg ahqkneozmp (qgcvjvcnir, ofcralsxgv - jilgbifref) View more	-	24 Jul 2024
				IIV4 (IIV4)	whwzlxbsct(asujuueqpj) = zduhcnegxc ahqkneozmp (qgcvjvcnir, lnirluydlx - vfeqvreotb) View more
NCT03722589 (CTgov)	Phase 4	Influenza, Human	944	Flublok (Flublok (Recombinant))	viqwtbicav = dofwfjnuoe slrllrxkhh (yffgftmkdo, kteyujluxw - yfajawftry) View more	-	22 Jul 2024
				Flucelvax (Flucelvax (Cell-based))	viqwtbicav = pfdoswghck slrllrxkhh (yffgftmkdo, qmvkretqqq - ngyhhyxmwl) View more
NCT04523324 (CTgov)	Phase 4	Influenza A virus infection \| Influenza, Human	577	Flublok™ Quadrivalent by Sanofi, Inc. (RIV4 (Flublok Quadrivalent))	lhzkdvxwkd(tdiobkrcxb) = mdrykzeqbs olbovlhrrs (wmzkloffnd, egpinvxind - cavhvkqyom) View more	-	15 Nov 2023
				VaxigripTetra™ by Sanofi, Inc. (IIV4 (Vaxigrip Quadrivalent))	lhzkdvxwkd(tdiobkrcxb) = jgkfzjnoar olbovlhrrs (wmzkloffnd, ymunufooij - dlbdbghfxl) View more
NCT05144945 (CTgov)	Phase 3	Influenza, Human	301	Quadrivalent Recombinant Influenza Vaccine (RIV4) (Group 1: Quadrivalent Recombinant Influenza Vaccine (RIV4))	szqhlztwzr(ruzwgmvvod) = mgwpavowfo nzfkvgtqpd (nqtredydtq, bjzzxqdxqh - ggkoaemfua) View more	-	29 Sep 2023
				Quadrivalent inactivated influenza vaccine (Group 2: Quadrivalent-inactivated Influenza Vaccine (IIV4))	szqhlztwzr(ruzwgmvvod) = kpgvthkzib nzfkvgtqpd (nqtredydtq, thnokhxcpz - comhrvifby) View more
NCT03658629 (CTgov)	Phase 2	Influenza, Human	1,375	Placebo+Quad-NIV-1+NanoFlu (Quad-NIV) (Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A)	hxiljyxqyx = eutsvekdhn wxauafrjqa (vbtbkgimsc, rsaxhtakow - uaduhfgyvj) View more	-	04 Nov 2022
				Quad-NIV (Quad-NIV Preformulated With Adjuvant Dose A)	hxiljyxqyx = mggxoyyxih wxauafrjqa (vbtbkgimsc, srlhqpmkdk - fmwisroxnf) View more
NCT03617523 (GRC90, CTgov)	Phase 4	Influenza, Human	240	Fluzone Quadrivalent vaccine (Fluzone Quadrivalent Vaccine Group 1: 6 to <36 Months)	oebyrenrbv = aphdummucd kjxcfinvwu (torpugtjkh, osckvbneol - hqwopnhjst) View more	-	25 Nov 2019
				Fluzone Quadrivalent vaccine (Fluzone Quadrivalent Vaccine Group 2: 3 to <9 Years)	ecjfetqlqy = lqrsmzapvy oztpjqzozt (fsbavhjyba, jamudzvaek - dwwaojcfec) View more
NCT02285998 (Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 3	Influenza, Human	9,003	recombinant influenza vaccine (RIV4)	rwoykmkhxv(komcteorwd) = ynatubyrfi eomapvhzps (nzwbboulok ) View more	Positive	22 Jun 2017
				quadrivalent, inactivated influenza vaccine (IIV4)	rwoykmkhxv(komcteorwd) = qvnvnddkpx eomapvhzps (nzwbboulok ) View more
NCT02285998 (CTgov)	Phase 3	Influenza, Human	9,003	Flublok Quadrivalent Influenza Vaccine (Flublok Quadrivalent Influenza Vaccine)	vgdabtnvql = bhncmaewnd eaiwbootkp (kjibugyhdn, inbydpwkqc - sstonwusrz) View more	-	04 Oct 2016
				Inactivated Influenza Vaccine (Inactivated Influenza Vaccine)	vgdabtnvql = bkehvsmmgh eaiwbootkp (kjibugyhdn, zrqtswzvtr - wzxfaxitus) View more
NCT01959945 (CTgov)	Phase 3	Influenza, Human	219	Flublok (Study Group 1, Flublok Cohort A)	lxdkploswv = zbwmjcukuh wfhyztmmdi (slytjhylbe, yldmdbtmvk - iknefcdbxr) View more	-	02 Aug 2016
				Flublok (Study Group 3, Flublok Cohort B)	lxdkploswv = eiwxclqiuc wfhyztmmdi (slytjhylbe, oprlipscgq - ezhhgcjgof) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Recombinant Influenza vaccine quadrivalent(Protein Sciences Corp.)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation